Astrazeneca plc

NASDAQ: AZN
$66.58
-$0.06 (-0.1%)
Closing Price on January 8, 2025

AZN Articles

Perhaps the move for a rapid exit by Britain from the European Union (or Brexit) may have been interrupted due to a political murder of M.P. Jo Cox on Thursday. As this was a member of parliament,...
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these...
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an improved formulation to a patent expiry and the opening of the floodgates for generic...
Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical...
Inovio Pharmaceuticals made waves early on Tuesday morning following an update for its human papillomavirus (HPV) treatment.
March 22, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Tuesday’s session. AstraZeneca PLC (NYSE: AZN) dropped about 2.5% on Tuesday...
Tuesday's top analyst initiations, upgrades and downgrades include AstraZeneca, 3D Systems, Barrick Gold, Home Depot, Oasis Petroleum and Whiting Petroleum.
AstraZeneca has announced that the European Commission granted marketing authorization for two of its treatments: Zurampic for gout and Brilique for heart attack patients.
The top analyst upgrades, downgrades and initiations seen on Monday, February 8 include Athenahealth, Baker Hughes, Cisco, LinkedIn, Orbital-ATK and Tableau Software.
Stocks tanked on Friday but were indicated sharply higher on Tuesday after the three-day weekend and after China’s gross domestic product met expectations. While investors may feel that every rally...
Good news for those who suffer from high levels of uric acid and from gout: the FDA has approved a new gout treatment.
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Wednesday's top analyst upgrades, downgrades and initiations include Aegerion Pharmaceuticals, Amazon.com, EMC, McDonald's, MetLife, Microsoft, SanDisk and Tyco International.
Tuesday's top analyst upgrades, downgrades and initiations include Bluebird Bio, Boston Beer, Etsy, Gilead Sciences, Pfizer, PMC-Sierra and Valeant Pharmaceuticals.
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.